Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRB2-associated and regulator of MAPK protein 1 (GAREM1) is an adaptor protein that functions downstream of the epidermal growth factor receptor (EGFR), regulating activation of the MAPK/ERK signaling pathway[2][5]. It is ubiquitously expressed and plays a role in intracellular signal transduction, contributing to cell proliferation and potentially other cellular processes[1][2][5]. The gene encodes multiple isoforms, and its paralog GAREM2 is brain-specific and involved in neuronal differentiation, while GAREM1 may also have unique roles through nuclear translocation mediated by a specific nuclear localization sequence[1]. No therapeutic drugs, clinical mechanisms of action, or recognized biomarker roles for GAREM1 were reported in the current sources. However, disease association with spondylocarpotarsal synostosis syndrome has been reported, and its involvement in cancer is possible due to its influence on mitogenic pathways[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GRB2-associated and regulator of MAPK protein 1 (GAREM1).